Cronos Group Inc.
Health
Performance
5.3
Risk
Sell
Buy
Curious about the Scores? Learn more.

Cronos Group Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

27.01.2026
On shaky ground. Struggling to find a clear direction.
22.01.2026
Slight bounce. Could be noise – or a comeback brewing.
19.12.2025
Risk creeping up. Stability not bulletproof anymore.
20.08.2025
Climbing out. Risks fading, but not out of the woods.

Cronos Group Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Cronos Group Inc. do? Business model and key facts

Get the full picture of Cronos Group Inc.: what it builds, where it operates, and how it makes money.

Cronos Group Inc. Profile

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees (FY): 459

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

shop
Company facts
Michael Ryan Gorenstein
CEO
459
Employees worldwide
shop
Performance
43.39%
Last 12 months
-73.79%
Last 5 years
shop
Growth
$117,62M
Revenue year
$40,02M
Net income
shop
Valuation
$1,04B
Market Cap
18.70
Price/Earnings Ratio

Stocks related to Cronos Group Inc.

Selected based on industry alignment and relative market positioning.

AMPH
Amphastar Pharmaceuticals, Inc.
26.25
-1.32%
6.3
Sell
Buy
Amphastar Pharmaceuticals, Inc.
EVO
Evotec SE
3.66
+0.55%
5.8
Sell
Buy
Evotec SE
COLL
Collegium Pharmaceutical, Inc.
45.32
-1.09%
6.3
Sell
Buy
Collegium Pharmaceutical, Inc.
PCRX
Pacira BioSciences, Inc.
19.85
-3.17%
5.9
Sell
Buy
Pacira BioSciences, Inc.
EMBC
Embecta Corp.
10.40
-3.17%
8.5
Sell
Buy
Embecta Corp.

Cronos Group Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.